Rayana AI
Account
RANI
HOLD / NEUTRALMeanRev
Composite
36.60
Technical
34.50
Fundamental
37.40
Rank
Price
0.90
Hurst
0.28
As of
Jul 23, 2026
Daily
Rani Therapeutics Holdings, Inc.
HealthcareBiotechnology

Rani Therapeutics is a clinical-stage biopharmaceutical company developing an oral capsule technology designed to deliver injectable medications such as proteins, peptides, antibodies, and oligonucleotides through the mouth instead of injections. The company's RaniPill platform is being tested with multiple drug candidates in its pipeline, including treatments for rheumatoid arthritis, obesity, rare diseases, and inflammatory conditions, along with a biosimilar program. Rani has established partnerships with several pharmaceutical companies to jointly develop and commercialize products using its delivery technology.

Market cap
$119.7M
P/E (trailing)
P/E (forward)
-4.48
PEG ratio
Dividend yield
Beta
0.71
52w range
0.45 – 3.87
Return on equity
-172.15%
Profit margin
0.00%
Revenue growth
Earnings growth
Price history

1Y: 0.85 (+76.8%) · range 0.46–2.85

Cycle position
33/ 100 cycle scoreAPPROACHING ENTRY
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT

entry readiness 33 · NOT READY · exit proximity 0

Conviction
34/ 100 · maturity 0%
Buildup.3334
EMA entry setup.4233
Fundamentals.2537
Volume profile
POC
0.79
Price vs POC
+8.3%
Overhead supply
46%
Runway
+1.0%

Value area 0.750.97 · 46% of 120d volume overhead · moderate overhead

Contributing sources

No source detections in the last 21 days.

Forward returns

Not yet labeled — the study prices these as positions mature.